Probiotix Health PLC - Change of Registered Office
RNS Number : 5760I
Probiotix Health PLC
19 April 2022
 

 

ProBiotix Health plc

("ProBiotix Health" or the "Company")

 

Change of registered office

ProBiotix Health plc (AQSE: PBX), a life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions, announces that it has changed its registered address to: First Floor, Zucchi Suite, Nostell Business Estate, Wakefield, WF4 1AB with immediate effect.

 

All formal notices and general correspondence should be sent to the new address.

 

For further information, please contact:

 

Probiotix Health plc

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 

 

 

Peterhouse Capital Limited

Tel: 020 7469 0930

Mark Anwyl (AQSE Corporate Adviser)

 

Duncan Vasey (Broker)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001 or probiotix@walbrookpr.com

Anna Dunphy

 

 

About ProBiotix Health plc

ProBiotix Health develops probiotics (live microbes that, when ingested, can alter the composition of the microbiome and improve human health) to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world.

 

ProBiotix Health's cholesterol reducing probiotic, Lactobacillus plantarum ECGC13110402 ("LP-LDL®), is manufactured in pharmaceutical GMP-certified facilities and protected worldwide by in the region of 5 patent families, comprising 27 patents and pending patent applications, and 22 trademarks.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXGZGMDRLNGZZG ]]>